Experience

Launch Therapeutics
• United States
• Biotechnology
• 1 - 100 Employee
• Chief Medical Officer

  • Jul 2022 - Present


BeiGene

• United States
• Biotechnology Research
• 700 & Above Employee

• Senior Vice President, Head of Clinical Development solid tumors

  • Nov 2019 - Jul 2022

  - Oversight of global development programs in solid tumors, including early-Phase (anti-OX40, anti-TIM3, HPK1 inhibitor, etc) and late-Phase assets (such as anti-PD1, anti-TIGIT, PARP inhibitor) - Chaired development governance committees with key input on development, regulatory, and safety strategies - Oversight of global development programs in solid tumors, including early-Phase (anti-OX40, anti-TIM3, HPK1 inhibitor, etc) and late-Phase assets (such as anti-PD1, anti-TIGIT, PARP inhibitor) - Chaired development governance committees with key input on development, regulatory, and safety strategies



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President, Global Medicine Lead, Immuno-Oncology

  • Oct 2017 - Nov 2019

  - Lead global product team for immuno-oncology in gastrointestinal (GI) and head and neck (HN) cancers and accountable for the overall strategy and for the successful development and commercialization of the program- Initiated 6 Phase 3 programs, including the positive HIMALAYA and TOPAZ-1 trials, for durvalumab and tremelimumab- Co-chaired GI strategy team and HNC strategy team

• Global Clinical Lead, Immuno-Oncology

  • Jan 2016 - Oct 2017

  - Lead the immuno-oncology development program in GI tumors for durvalumab and trememlimumab- Part of development team for durvalumab bladder submission - first approval for durvalumab- Co-chaired GI strategy team



Eli Lilly and Company

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Medical Fellow

  • Oct 2013 - Jan 2016

  - Cyramza Development Lead for GI cancer: Lead late-phase programs and global submissions in GI cancers: Cyramza 2L mCRC submission (RAISE); HCC Ph3s (REACH and REACH-2), BTC Phase 2- Product Team Lead, Erbitux: Accountable for brand strategy and life cycle plan for Erbitux; co-chair of Join Development Committee of Erbitux alliance with BMS and Merck Serono- Chaired GI tumor strategy group for early and late Phase pipeline

• Senior Medical Advisor

  • Oct 2010 - Sep 2013

  - Erbitux Development Lead for CRC and HNC- Erbitux HNC submission (EXTREME) and mCRC submission (CRYSTAL)- K-Ras companion diagnostic PMA

• Medical Advisor

  • Dec 2006 - Sep 2010

  - Erbitux Development Lead for CRC and HNC- Erbitux HNC submission (EXTREME) and mCRC submission (CRYSTAL)- K-Ras companion diagnostic PMA- Alimta Development lead in HNC Phase 3 program- Enzastaurin development in glioblastoma


Washington University School of Medicine
• United States
• Medical Practices
• Instructor

  • Jul 2005 - Nov 2006